pilocarpine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
tricyclic compounds 2166 92-13-7

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • salagen
  • pilocarpine nitrate
  • pilocarpine
  • ocucarpine
  • pilocarpol
  • pilokarpin
  • syncarpine
  • (+)-Pilocarpine
  • pilocarpine hydrochloride
  • pilocarpine HCl
A slowly hydrolyzed muscarinic agonist with no nicotinic effects. Pilocarpine is used as a miotic and in the treatment of glaucoma.
  • Molecular weight: 208.26
  • Formula: C11H16N2O2
  • CLOGP: -0.20
  • LIPINSKI: 0
  • HAC: 4
  • HDO: 0
  • TPSA: 44.12
  • ALOGS: -2
  • ROTB: 3
  • Status: OFP
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
15 mg O
10 mg P
0.40 ml None
40 mg ointment

ADMET properties:

PropertyValueReference
fu (Fraction unbound in plasma) 0.92 % Kawashima H, Watanabe R, Esaki T, Kuroda M, Nagao C, Natsume-Kitatani Y, Ohashi R, Komura H, Mizuguchi K
BA (Bioavailability) 100 %

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
azlogd74 LogD at pH 7.4 0.203 High 1
caco2-efflux Caco-2 efflux ratio (BA/AB) 1.905 High 1
caco2-intrinsic-papp Caco-2 intrinsic apparent permeability 7.430 10^-6 cm/s High 1
dh-clint Dog hepatocyte intrinsic clearance 2.877 uL/min/10^6 cells High 1
dppb Dog plasma protein binding (% unbound) 76.270 % High 1
fcs-ppb Fetal calf serum protein binding (% unbound) 69.520 % High 1
herg hERG pIC50 4.192 pIC50 High 1
hh-clint Human hepatocyte intrinsic clearance 1.197 uL/min/10^6 cells High 1
hlm-clint Human liver microsomal intrinsic clearance 3.981 uL/min/mg protein High 1
hppb Human plasma protein binding (% unbound) 63.850 % High 1
kinase-safety-class ACVR2A,ACVR2B,AXL,BRAF,BTK,CAMK2D,CDK5,CDK9,DYRK1B,EIF2AK3,ERBB2,GRK2,MAP3K21,MAPK7,NTRK2,PDK1,PDK2,PRKDC,SIK2,STK33,TEK 21
kinase-selectivity-class GRK2 1
mdck-mdr1-efflux MDCK-MDR1 efflux ratio 2.234 High 1
mh-clint Mouse hepatocyte intrinsic clearance 7.907 High 1
mppb Mouse plasma protein binding (% unbound) 79.510 High 1
nih-mdck-mdr1-efflux NIH MDCK-MDR1 efflux ratio 3.119 High 1
pfas-class PFAS structural alert (1 = True, 0 = False) 0
pppb Pig plasma protein binding (% unbound) 83.590 % High 1
rh-clint Rat hepatocyte intrinsic clearance 1.758 uL/min/10^6 cells High 1
rh-fuinc Rat hepatocyte fraction unbound in incubation 91.460 % High 1
rppb Rat plasma protein binding (% unbound) 67.880 % High 1
solubility-dd Solubility at pH 7.4 in DMSO 914.113 uM High 1

Approvals:

DateAgencyCompanyOrphan
July 29, 1974 FDA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Glaucoma 64.23 15.97 34 8743 20721 90598949
Dry eye 58.61 15.97 47 8730 57884 90561786
Vitreous detachment 56.37 15.97 17 8760 2361 90617309
Eye pain 53.77 15.97 40 8737 44128 90575542
Limb injury 53.50 15.97 35 8742 31473 90588197
Occult blood 51.98 15.97 14 8763 1297 90618373
Angioplasty 50.33 15.97 14 8763 1463 90618207
Eye irritation 46.42 15.97 33 8744 33945 90585725
Calcification of muscle 45.90 15.97 9 8768 200 90619470
Peripheral vascular disorder 43.19 15.97 18 8759 6413 90613257
Vision blurred 42.68 15.97 53 8724 110240 90509430
Visual impairment 40.98 15.97 57 8720 132308 90487362
Choking 40.91 15.97 21 8756 12012 90607658
Vitreous floaters 40.41 15.97 18 8759 7531 90612139
Vitreoretinal traction syndrome 39.23 15.97 6 8771 27 90619643
Transient ischaemic attack 35.33 15.97 31 8746 43145 90576525
Crepitations 34.66 15.97 17 8760 8835 90610835
Corneal oedema 34.18 15.97 11 8766 1890 90617780
Hot flush 32.16 15.97 34 8743 59454 90560216
Spinal osteoarthritis 31.84 15.97 21 8756 19127 90600543
Coronary artery disease 31.30 15.97 26 8751 33597 90586073
Acute myocardial infarction 30.46 15.97 26 8751 34864 90584806
Iritis 27.07 15.97 11 8766 3675 90615995
Cardiac failure congestive 26.87 15.97 40 8737 98654 90521016
Tanning 26.40 15.97 5 8772 92 90619578
Haemorrhage 26.28 15.97 33 8744 69336 90550334
Sputum discoloured 26.01 15.97 19 8758 20372 90599298
Intraocular pressure increased 25.92 15.97 13 8764 7080 90612590
Bronchial wall thickening 25.19 15.97 9 8768 2122 90617548
Iron deficiency 24.89 15.97 14 8763 9598 90610072
Urinary retention 24.84 15.97 24 8753 37720 90581950
Body temperature fluctuation 24.61 15.97 9 8768 2266 90617404
Blood pressure increased 24.50 15.97 57 8720 197160 90422510
Accommodation disorder 24.09 15.97 6 8771 408 90619262
Pulmonary congestion 22.31 15.97 17 8760 19416 90600254
Psychiatric decompensation 22.19 15.97 8 8769 1935 90617735
Myocardial infarction 22.05 15.97 38 8739 105934 90513736
Conjunctival hyperaemia 21.72 15.97 9 8768 3160 90616510
Visual acuity reduced 21.57 15.97 18 8759 23392 90596278
Ocular hyperaemia 21.33 15.97 21 8756 33777 90585893
Blood pressure diastolic increased 21.08 15.97 14 8763 12892 90606778
Productive cough 20.64 15.97 31 8746 77032 90542638
Bicytopenia 20.21 15.97 9 8768 3762 90615908
Blood pressure systolic decreased 20.02 15.97 12 8765 9258 90610412
Increased tendency to bruise 19.67 15.97 13 8764 11877 90607793
Instillation site pain 19.29 15.97 6 8771 924 90618746
Headache 19.26 15.97 146 8631 862600 89757070
Acne 18.52 15.97 18 8759 28489 90591181
Open fracture 18.40 15.97 5 8772 479 90619191
Pulmonary oedema 18.11 15.97 26 8751 62054 90557616
Vasculitis 17.97 15.97 16 8761 22677 90596993
Post procedural discharge 17.95 15.97 5 8772 525 90619145
Endometritis 17.78 15.97 6 8771 1194 90618476
Photopsia 17.75 15.97 9 8768 5015 90614655
Ulcerative keratitis 17.74 15.97 8 8769 3445 90616225
Platelet count increased 17.10 15.97 15 8762 20844 90598826
Myalgia 16.91 15.97 46 8731 175079 90444591
Exposure to communicable disease 16.85 15.97 5 8772 657 90619013
Systemic lupus erythematosus 16.82 15.97 7 8770 361889 90257781
Epstein-Barr virus associated lymphoma 16.52 15.97 5 8772 703 90618967
Retinal tear 16.47 15.97 6 8771 1496 90618174
Toxicity to various agents 16.14 15.97 4 8773 287842 90331828
Pupillary disorder 16.13 15.97 4 8773 267 90619403

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Vitreous detachment 100.48 24.93 19 1474 997 42618845
Visual impairment 96.39 24.93 41 1452 43072 42576770
Retinal tear 75.36 24.93 15 1478 1029 42618813
Retinal detachment 74.30 24.93 21 1472 6504 42613338
Vitreous floaters 73.49 24.93 19 1474 4211 42615631
Intraocular pressure increased 52.51 24.93 16 1477 6417 42613425
Rhegmatogenous retinal detachment 45.75 24.93 7 1486 100 42619742
Vitreoretinal traction syndrome 41.93 24.93 5 1488 7 42619835
Vision blurred 41.74 24.93 25 1468 53674 42566168
Ocular hyperaemia 41.70 24.93 17 1476 15946 42603896
Photopsia 37.94 24.93 10 1483 2382 42617460
Lens dislocation 36.67 24.93 6 1487 134 42619708
Tumour flare 34.37 24.93 8 1485 1145 42618697
Headache 31.22 24.93 40 1453 239329 42380513
Eye pain 30.84 24.93 14 1479 17016 42602826
Treatment failure 28.75 24.93 21 1472 62603 42557239
Miosis 27.37 24.93 12 1481 13434 42606408

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Glaucoma 79.52 16.06 37 8131 22480 110558651
Limb injury 66.87 16.06 39 8129 37597 110543534
Vitreous detachment 59.01 16.06 17 8151 2648 110578483
Angioplasty 54.69 16.06 15 8153 1956 110579175
Vitreous floaters 51.90 16.06 21 8147 9113 110572018
Occult blood 50.92 16.06 14 8154 1842 110579289
Calcification of muscle 48.87 16.06 9 8159 188 110580943
Intraocular pressure increased 48.36 16.06 21 8147 10855 110570276
Vitreoretinal traction syndrome 47.76 16.06 7 8161 31 110581100
Choking 44.73 16.06 22 8146 15088 110566043
Dry eye 44.06 16.06 35 8133 55758 110525373
Peripheral vascular disorder 42.90 16.06 18 8150 8558 110572573
Crepitations 38.86 16.06 18 8150 10817 110570314
Eye pain 38.64 16.06 31 8137 50068 110531063
Transient ischaemic attack 37.87 16.06 34 8134 63948 110517183
Lens dislocation 36.47 16.06 7 8161 184 110580947
Visual impairment 36.09 16.06 47 8121 134381 110446750
Corneal oedema 35.47 16.06 12 8156 3161 110577970
Hot flush 29.41 16.06 30 8138 66006 110515125
Cardiac failure congestive 27.61 16.06 44 8124 150956 110430175
Sputum discoloured 27.51 16.06 20 8148 27925 110553206
Tanning 27.35 16.06 5 8163 100 110581031
Haemorrhage 26.62 16.06 36 8132 106656 110474475
Urinary retention 26.32 16.06 29 8139 69654 110511477
Tumour flare 26.01 16.06 8 8160 1559 110579572
Spinal osteoarthritis 25.88 16.06 17 8151 20166 110560965
Vision blurred 25.54 16.06 39 8129 128983 110452148
Iritis 24.06 16.06 10 8158 4642 110576489
Bronchial wall thickening 23.98 16.06 9 8159 3198 110577933
Blood pressure increased 23.45 16.06 56 8112 258317 110322814
Body temperature fluctuation 22.56 16.06 9 8159 3764 110577367
Coronary artery disease 22.31 16.06 27 8141 71663 110509468
Eye irritation 22.25 16.06 19 8149 33433 110547698
Miosis 22.24 16.06 16 8152 21967 110559164
Conjunctival hyperaemia 21.89 16.06 10 8158 5821 110575310
Pulmonary congestion 21.44 16.06 18 8150 30948 110550183
Endometritis 20.62 16.06 6 8162 968 110580163
Acne 20.20 16.06 18 8150 33502 110547629
Iron deficiency 19.97 16.06 14 8154 18462 110562669
Blood pressure diastolic increased 19.75 16.06 14 8154 18793 110562338
Open fracture 19.31 16.06 5 8163 523 110580608
Productive cough 19.12 16.06 32 8136 114273 110466858
Myocardial infarction 18.92 16.06 43 8125 192040 110389091
Ocular surface disease 18.75 16.06 4 8164 180 110580951
Exposure to communicable disease 18.70 16.06 5 8163 592 110580539
Headache 18.61 16.06 120 8048 882257 109698874
Accommodation disorder 18.26 16.06 5 8163 648 110580483
Ocular hyperaemia 17.77 16.06 18 8150 39268 110541863
Instillation site pain 17.60 16.06 5 8163 741 110580390
Bicytopenia 17.58 16.06 9 8159 6715 110574416
Acute myocardial infarction 17.54 16.06 26 8142 83751 110497380
Post procedural discharge 17.36 16.06 5 8163 777 110580354
Ulcerative keratitis 17.34 16.06 8 8160 4758 110576373
Weight increased 17.30 16.06 69 8099 419575 110161556
Rhegmatogenous retinal detachment 17.17 16.06 4 8164 270 110580861
Visual acuity reduced 16.90 16.06 16 8152 32157 110548974
Choroidal effusion 16.73 16.06 5 8163 885 110580246
Angle closure glaucoma 16.35 16.06 7 8161 3492 110577639

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC N07AX01 NERVOUS SYSTEM
OTHER NERVOUS SYSTEM DRUGS
PARASYMPATHOMIMETICS
Other parasympathomimetics
ATC S01EB01 SENSORY ORGANS
OPHTHALMOLOGICALS
ANTIGLAUCOMA PREPARATIONS AND MIOTICS
Parasympathomimetics
ATC S01EB51 SENSORY ORGANS
OPHTHALMOLOGICALS
ANTIGLAUCOMA PREPARATIONS AND MIOTICS
Parasympathomimetics
FDA MoA N0000000104 Cholinergic Muscarinic Agonists
FDA MoA N0000175369 Cholinergic Agonists
MeSH PA D008916 Miotics
MeSH PA D018377 Neurotransmitter Agents
MeSH PA D018678 Cholinergic Agents
MeSH PA D018679 Cholinergic Agonists
MeSH PA D018721 Muscarinic Agonists
FDA EPC N0000175884 Cholinergic Receptor Agonist
CHEBI has role CHEBI:39456 antiglaucoma drug
CHEBI has role CHEBI:35610 antineoplastic agent
CHEBI has role CHEBI:66981 ophthalmology drug

Related Drugs by ATC class:

N07AX Other parasympathomimetics 2 drugs
cevimelinecholine alfoscerate
S01EB Parasympathomimetics 9 drugs
aceclidineacetylcholinecarbacholdemecariumechothiophatefluostigmineneostigmineparaoxonphysostigmine

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Ocular hypertension indication 4210003 DOID:9282
Presbyopia indication 41256004 DOID:11638
Open-angle glaucoma indication 84494001 DOID:1067
Aptyalism indication 87715008
Xerostomia Secondary to Radiation Therapy indication
Xerostomia Secondary to Sjogren's Syndrome indication
Primary Closed Angle Glaucoma indication
Bronchospasm contraindication 4386001
Keratitis contraindication 5888003 DOID:4677
Chronic obstructive lung disease contraindication 13645005 DOID:3083
Retinal detachment contraindication 42059000 DOID:5327
Hepatic failure contraindication 59927004
Iritis contraindication 65074000 DOID:1406
Cholecystitis contraindication 76581006 DOID:1949
Kidney stone contraindication 95570007
Disorder of biliary tract contraindication 105997008 DOID:9741
Acute disease of cardiovascular system contraindication 128487001
Calculus in biliary tract contraindication 266474003
Angle-closure glaucoma contraindication 392291006 DOID:13550
Anterior uveitis contraindication 410692006 DOID:1407
Acute exacerbation of asthma contraindication 708038006
Psychiatric Disturbance contraindication
Pupillary Block Glaucoma contraindication




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 7.04 Basic

Orange Book patent data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
0.4% QLOSI ORASIS PHARMS N217836 Oct. 17, 2023 RX SOLUTION/DROPS OPHTHALMIC 10639297 Aug. 18, 2037 TREATMENT OF PRESBYOPIA
0.4% QLOSI ORASIS PHARMS N217836 Oct. 17, 2023 RX SOLUTION/DROPS OPHTHALMIC 11129812 Aug. 18, 2037 TREATMENT OF PRESBYOPIA
0.4% QLOSI ORASIS PHARMS N217836 Oct. 17, 2023 RX SOLUTION/DROPS OPHTHALMIC 11974986 Aug. 18, 2037 TREATMENT OF PRESBYOPIA
0.4% QLOSI ORASIS PHARMS N217836 Oct. 17, 2023 RX SOLUTION/DROPS OPHTHALMIC 9867810 Aug. 18, 2037 TREATMENT OF PRESBYOPIA
1.25% VUITY ABBVIE N214028 Oct. 28, 2021 DISCN SOLUTION/DROPS OPHTHALMIC 10610518 April 24, 2039 TREATMENT OF PRESBYOPIA IN ADULTS BY ADMINISTRATION OF PILOCARPINE HCI FORMULATION ONCE DAILY
1.25% VUITY ABBVIE N214028 Oct. 28, 2021 DISCN SOLUTION/DROPS OPHTHALMIC 10610518 April 24, 2039 TREATMENT OF PRESBYOPIA IN ADULTS BY ADMINISTRATION OF PILOCARPINE HCI FORMULATION TWICE DAILY
1.25% VUITY ABBVIE N214028 Oct. 28, 2021 DISCN SOLUTION/DROPS OPHTHALMIC 10610518 April 24, 2039 USE OF VUITY FOR THE TREATMENT OF PRESBYOPIA IN ADULTS
1.25% VUITY ABBVIE N214028 Oct. 28, 2021 DISCN SOLUTION/DROPS OPHTHALMIC 11285134 April 24, 2039 TREATMENT OF PRESBYOPIA IN ADULTS BY ADMINISTRATION OF PILOCARPINE HCI FORMULATION ONCE DAILY
1.25% VUITY ABBVIE N214028 Oct. 28, 2021 DISCN SOLUTION/DROPS OPHTHALMIC 11285134 April 24, 2039 TREATMENT OF PRESBYOPIA IN ADULTS BY ADMINISTRATION OF PILOCARPINE HCI FORMULATION TWICE DAILY
1.25% VUITY ABBVIE N214028 Oct. 28, 2021 DISCN SOLUTION/DROPS OPHTHALMIC 11285134 April 24, 2039 USE OF VUITY FOR THE TREATMENT OF PRESBYOPIA IN ADULTS

Orange Book exclusivity data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRouteExclusivity dateDescription
1.25% VUITY ABBVIE N214028 Oct. 28, 2021 DISCN SOLUTION/DROPS OPHTHALMIC March 28, 2026 ADDITION OF SECOND DOSE FOR TREATMENT OF PRESBYOPIA IN ADULTS
0.4% QLOSI ORASIS PHARMS N217836 Oct. 17, 2023 RX SOLUTION/DROPS OPHTHALMIC Oct. 17, 2026 NEW PRODUCT

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Muscarinic acetylcholine receptor M3 GPCR AGONIST EC50 6.97 SCIENTIFIC LITERATURE IUPHAR
Muscarinic acetylcholine receptor M1 GPCR AGONIST EC50 7.02 SCIENTIFIC LITERATURE
Muscarinic acetylcholine receptor M2 GPCR AGONIST EC50 6.95 SCIENTIFIC LITERATURE
Muscarinic acetylcholine receptor M4 GPCR AGONIST EC50 7.15 SCIENTIFIC LITERATURE
Muscarinic acetylcholine receptor M5 GPCR AGONIST EC50 7 SCIENTIFIC LITERATURE
Muscarinic acetylcholine receptor M1 GPCR Ki 5.51 CHEMBL
Muscarinic acetylcholine receptor M1 GPCR EC50 5.16 CHEMBL
Muscarinic acetylcholine receptor DM1 GPCR Ki 5.55 CHEMBL
Muscarinic acetylcholine receptor GPCR Ki 7.08 CHEMBL
Muscarinic acetylcholine receptor M2 GPCR Ki 5.01 CHEMBL

External reference:

IDSource
D00525 KEGG_DRUG
148-72-1 SECONDARY_CAS_RN
54-71-7 SECONDARY_CAS_RN
4018207 VANDF
4018208 VANDF
4018209 VANDF
4020904 VANDF
C0031923 UMLSCUI
CHEBI:8207 CHEBI
9PL PDB_CHEM_ID
CHEMBL550 ChEMBL_ID
DB01085 DRUGBANK_ID
CHEMBL1200330 ChEMBL_ID
CHEMBL611494 ChEMBL_ID
CHEMBL1213136 ChEMBL_ID
D010862 MESH_DESCRIPTOR_UI
5910 PUBCHEM_CID
305 IUPHAR_LIGAND_ID
01MI4Q9DI3 UNII
103244 RXNORM
1396 MMSL
20709 MMSL
3317 MMSL
44345 MMSL
5299 MMSL
5300 MMSL
72427 MMSL
73122 MMSL
d04031 MMSL
001693 NDDF
001694 NDDF
001695 NDDF
372895002 SNOMEDCT_US
387035001 SNOMEDCT_US
395827004 SNOMEDCT_US
90356005 SNOMEDCT_US
01MI4Q9DI3 INXIGHT DRUGS

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
VUITY HUMAN PRESCRIPTION DRUG LABEL 1 0074-7098 SOLUTION/ DROPS 12.50 mg OPHTHALMIC NDA 26 sections
Pilocarpine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0115-5911 TABLET, FILM COATED 7.50 mg ORAL ANDA 23 sections
Pilocarpine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0115-5922 TABLET, FILM COATED 5 mg ORAL ANDA 23 sections
Pilocarpine hydrochloride Human Prescription Drug Label 1 0228-2801 TABLET, FILM COATED 5 mg ORAL NDA AUTHORIZED GENERIC 21 sections
Pilocarpine hydrochloride Human Prescription Drug Label 1 0228-2837 TABLET, FILM COATED 7.50 mg ORAL NDA AUTHORIZED GENERIC 21 sections
Pilocarpine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0527-1313 TABLET, FILM COATED 5 mg ORAL ANDA 24 sections
Pilocarpine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0527-1407 TABLET, FILM COATED 7.50 mg ORAL ANDA 24 sections
Pilocarpine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 10135-589 TABLET, FILM COATED 5 mg ORAL ANDA 22 sections
Pilocarpine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 10135-590 TABLET, FILM COATED 7.50 mg ORAL ANDA 22 sections
Pilocarpine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 10135-680 TABLET, FILM COATED 5 mg ORAL ANDA 23 sections
Pilocarpine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 17478-223 SOLUTION/ DROPS 10 mg OPHTHALMIC ANDA 24 sections
Pilocarpine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 17478-224 SOLUTION/ DROPS 20 mg OPHTHALMIC ANDA 24 sections
Pilocarpine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 17478-226 SOLUTION/ DROPS 40 mg OPHTHALMIC ANDA 24 sections
PILOCARPINE HYDROCHLORIDE HUMAN PRESCRIPTION DRUG LABEL 1 21695-368 SOLUTION/ DROPS 10 mg CONJUNCTIVAL NDA 14 sections
Pilocarpine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 21695-601 TABLET 5 mg ORAL ANDA 23 sections
Pilocarpine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 50268-652 TABLET, FILM COATED 5 mg ORAL ANDA 24 sections
Pilocarpine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 54868-5436 TABLET, FILM COATED 5 mg ORAL ANDA 24 sections
Salagen Human Prescription Drug Label 1 59212-705 TABLET, FILM COATED 5 mg ORAL NDA 21 sections
Salagen Human Prescription Drug Label 1 59212-775 TABLET, FILM COATED 7.50 mg ORAL NDA 21 sections
Pilocarpine Hydrochloride Human Prescription Drug Label 1 59651-224 TABLET, FILM COATED 5 mg ORAL ANDA 20 sections
Pilocarpine Hydrochloride Human Prescription Drug Label 1 59651-224 TABLET, FILM COATED 5 mg ORAL ANDA 20 sections
Pilocarpine Hydrochloride Human Prescription Drug Label 1 59651-225 TABLET, FILM COATED 7.50 mg ORAL ANDA 20 sections
Pilocarpine Hydrochloride Human Prescription Drug Label 1 59651-225 TABLET, FILM COATED 7.50 mg ORAL ANDA 20 sections
Pilocarpine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 60219-1745 SOLUTION/ DROPS 10 mg OPHTHALMIC ANDA 23 sections
Pilocarpine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 60219-1746 SOLUTION/ DROPS 20 mg OPHTHALMIC ANDA 23 sections
Pilocarpine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 60219-1747 SOLUTION/ DROPS 40 mg OPHTHALMIC ANDA 23 sections
Pilocarpine Hydrochloride Ophthalmic HUMAN PRESCRIPTION DRUG LABEL 1 60219-2366 SOLUTION/ DROPS 12.50 mg OPHTHALMIC ANDA 23 sections
Pilocarpine Hydrochloride Ophthalmic HUMAN PRESCRIPTION DRUG LABEL 1 60219-2649 SOLUTION/ DROPS 12.50 mg OPHTHALMIC ANDA 23 sections
Pilocarpine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 60219-5922 TABLET, FILM COATED 5 mg ORAL ANDA 23 sections
Pilocarpine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 61314-203 SOLUTION/ DROPS 10 mg OPHTHALMIC NDA authorized generic 23 sections